Up­sized and top-of-the-range: Fall round of biotech IPOs starts with a sol­id hit for Prin­cip­ia

Any­one con­sid­er­ing a biotech IPO will want to pay close at­ten­tion to the lat­est suc­cess sto­ry on Nas­daq.

Prin­cip­ia Bio­phar­ma raised $106 mil­lion from a beefed up IPO, sell­ing 6.2 mil­lion shares at $17 a pop — the top end of the range. The South San Fran­cis­co-based biotech — with an ex­ec­u­tive crew drawn from the ranks at Roche/Genen­tech — will now start trad­ing un­der the $PRNB sym­bol.

Why is it im­por­tant? 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER